See also this year's filing and all EDGAR filings for this company.
PDF Report 0000872589_2023_REGENERON_PHARMACEUTICALS_INC.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.2440412887081639, 'aggregate_val': 7954400000, 'exp_sum': 6394000000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 2115900000, 'ResearchAndDevelopmentExpense': 3592500000, 'remainder_Expenses': 685600000}} |
Graph
Absolute values for 0000872589, REGENERON PHARMACEUTICALS INC.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 15,884,100,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 915,500,000 |
| 2 | PropertyPlantAndEquipmentNet | 0 |
| 3 | remainder_Assets | 12,414,900,000 |
| 4 | LiabilitiesCurrent | 3,141,300,000 |
| 5 | LiabilitiesNoncurrent | 2,689,200,000 |
| 6 | remainder_Liabilities | 720,000,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 2,115,900,000 |
| 9 | ResearchAndDevelopmentExpense | 3,592,500,000 |
| 10 | remainder_Expenses | 2,246,000,000 |
| 11 | remainder_Revenues | 12,172,900,000 |
| 12 | remainder_NetIncome | 119,900,000 |
| 13 | remainder_ComprehensiveNetIncome | -212,600,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 29,214,500,000 |
| 1 | Liabilities | 6,550,500,000 |
| 2 | Expenses | 7,954,400,000 |
| 3 | Revenues | 12,172,900,000 |
| 4 | StockholdersEquity | 22,664,000,000 |
| 5 | NetIncome | 4,338,400,000 |
| 6 | ComprehensiveNetIncome | 4,232,100,000 |
| 7 | BaseVar | 28,112,400,000 |
| 8 | EconomicCapitalRatio | 2.42 |
Edgar->Model Mapping
Feature Distribution
Change over Time
